HB9661Introduced in the House
Expedited Access to Biosimilars Act
Introduced by Nicholas Langworthy, District NY-23
What does this bill do?
Plain-English breakdown
Checking for a plain-English summary…
Official description
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Where it stands
Referred to the House Committee on Energy and Commerce.
July 14, 2026
How did lawmakers vote?
No recorded vote is available for this bill yet.
What do people think?
Citizen Voice
How would you vote on this bill?
An unofficial public opinion poll. It does not affect the bill or the official vote.
One response per device. Location is self-reported and not verified. Results are informal and not a scientific survey.
Bill history
Introduced in House
Referred to the House Committee on Energy and Commerce.
Verify the information
Our commitment to neutrality
We provide factual information only. We never tell you which politicians or bills to support, and we do not rank, score, or endorse anyone.